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Malignant otitis externa is an emerging problem in developing countries. We are seeing an increase in
this condition in elderly people with diabetes. This paper reports on a retrospective chart review of 18
patients with malignant otitis externa in a tertiary care center. We have comprehensively discussed the
clinical features, diagnosis, and management of this disease. Malignant otitis externa is suspected in
high-risk patients, i.e., elderly individuals with diabetes, immunocompromised, and immunosuppressed
patients. Early and prolonged use of appropriate antimicrobials will reduce the morbidity and mortality
associated with this condition. The role of surgery is limited to biopsy, the draining of microabscesses, or
the removal of sequestrum.
Copyright  2013, Asia Paciﬁc League of Clinical Gerontology & Geriatrics. Published by Elsevier Taiwan
LLC.
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Malignant otitis externa (MOE) is a rare, rapidly spreading, life-
threatening invasive infection of the external auditory canal and
the lateral skull base. Toulmouche is credited with ﬁrst describing
this condition.1 Meltzer and Kelemen reported a case of pyocyaneus
osteomyelitis of the temporal bone, mandible and zygoma, which is
believed to be the ﬁrst report of this condition in modern litera-
ture.2 Chandler coined the term “malignant external otitis” and
described the clinical characteristics of this disease.3 Necrotizing
otitis externa and skull base osteomyelitis are the other terms used
to describe this condition.
The incidence of MOE has increased in recent times. This may be
attributed to an increase in awareness of the disease, better diag-
nostic modalities, and an increase in the geriatric and diabetic
population in India.4 MOE was initially described as a disease of an
elderly patient with diabetes.3 Since then, this entity has been
described by many in the geriatric population. The geriatric pop-
ulation is more prone to cleaning their ears due to dry and itchy
skin. In addition, diabetes alters the pH of the external auditory
canal and predisposes people to infection by altering the immune
response. MOE, although rare, has been reported in the immuno-
suppressed and in children., and Neck Surgery, Sri Ram-
ur, Chennai 38, India.
. Prasanna Kumar).
linical Gerontology & Geriatrics. PThe awareness and understanding of this disease has changed
the way in which it is being dealt with. In this article, we retro-
spectively audit the case records of patients diagnosed with, and
managed for, malignant otitis externa.
2. Case series
The case records of 18 patients diagnosed as having malignant
otitis externa and managed by the senior author or under his su-
pervision over a period of 4 years from 2008 to 2011 were included
in the study. This study was carried out in the department of Ears,
Nose, and Throat, Head, and Neck surgery of a tertiary care hospital
in South India. The descriptive data noted were age, sex, comorbid
conditions, symptoms and signs at presentation, investigation done
(including bacterial culture, fungal smear, and culture), treatment
(antibiotics given, route, and duration), adverse events, complica-
tions, and outcome. All these datawere summarized, tabulated, and
analyzed as shown in Table 1. (Initially a clinical diagnosis of MOE
wasmade in 23 patients, but because biopsy of granulations proved
to be malignant in ﬁve patients, they were excluded from the
series).
3. Discussion
MOE is a rapidly spreading infection, which originates at the
bony cartilaginous junction of the external auditory canal. Its eti-
ology is attributed to infection after trivial trauma, such as that ofublished by Elsevier Taiwan LLC. Open access under CC BY-NC-ND license.
Table 1
Details of the demographics, clinical, and microbiological outcomes of 18 patients
treated for malignant otitis externa in the tertiary care hospital.
Age at diagnosis
(mean  SD)
62  8.5 years
Sex, male:female 8:1
Ear affected (right:left) 1:1
Comorbid condition Diabetes mellitus (100),
chronic kidney disease (30)
Cranial nerves involved
Facial nerve only (VII) 12/18 (66.6)
Multiple cranial nerves
(VII, IX,X and XII)
3/18 (16.6)
Presenting symptoms Ear ache (nocturnal; 100)
Persistent ear discharge (100)
Facial weakness (66.6)
Duration of symptoms lasting 45 days (average)
Presenting signs Ear discharge (100)
External auditory canal (EAC) granulation (100)
Tenderness EAC inferiorly (100)
Facial weakness (66.6)
Organism isolateda Bacteria:
 Pseudomonas aeruginosa, 9/18 (50)
 Staphylococcus aureus, 4/18 (22)
 Enterococcus faecalis, 1/18 (5.5)
Fungi:
 Aspergillus fumigatus, 2/18 (11)
 Candida albicans, 1/18 (5.5)
Polymicrobial:
 P. aeruginosa þ A. fumigates, 2/18
 S. aureus þ C. albicans, 1/18
 S. aureus þ E. faecalis, 1/18
 P. aeruginosa þ S. aureus, 1/18
No growth, 6/18 (33)
Biopsyb Done in 8 cases to rule out malignancy in
suspected malignant otitis externa sent
for histopathological examination:
 Squamous cell carcinoma (malignancy)
in 5 patients (excluded from the series)
 Nonspeciﬁc chronic inﬂammatory
changes in 3 patients
Treatment
Medical Initial intravenous antimicrobial given:
Piperacillin-tazobactam, 8/18
Ciproﬂoxacin, 4/18
Cefoperazone-sulbactum, 3/18
Linezolid, 1/18
Amphotericin B, 2/18
Followed by oral antibiotics:
Ciproﬂoxacin
Cefpodoxime
Ceﬁxime
Itraconazole
Surgical Biopsy 3/18; microabscess, 1/18;
sequestrum 1/18
Status (post-treatment) 15 complete recoveries
2 relapses
2 mortalites
Data are presented as n (%).
a 5 patients had polymicrobial infection that was isolated on culture and
sensitivity.
b Biopsy was taken in all suspected cases of malignant otitis externa not
responding to treatment or on clinical suspicion. All 5 cases that had evidence of
malignancy on histopathological examination were excluded from the series.
Fig. 1. Granulation in the external auditory canal.
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periauricular tissue that subsequently spreads through the ﬁssures
of Santorini to the adjoining skull base, causing periostitis, osteitis,
chondritis, osteomyelitis and, eventually, multiple cranial nerve
palsies.
Elderly people with diabetes are more prone to MOE. It is well
documented that diabetes causes endarteritis and micro-
angiopathy, leading to hypoperfusion in the subcutaneous tissue.6
Diabetes reduces the chemotactic and bactericidal activity ofhuman polymorphonuclear leukocytes. It also causes immune
dysfunction and poor granulocyte function, which is believed to
prolong the disease.7,8 Driscoll et al. have suggested that the
increased pH of the cerumen in patients with diabetes may be a
contributing factor.9
In our study, the average age at diagnosis of MOE was 62  8.5
years. All of the patients had uncontrolled type 2 diabetes mellitus.
Of these, 25% had coexisting chronic kidney disease. MOE, although
rare, has been reported in childrenwho are immunodeﬁcient, those
undergoing chemotherapy, or in transplantees who are on immu-
nosuppressive therapy.10e12 Others who are at risk are those
suffering from malnutrition and HIV.13,14
Diagnosis of MOE requires a high index of suspicion. There are
no universally accepted speciﬁc criteria.11 The presence of persis-
tent pain out of proportion to changes seen at otoscopy, purulent
otorrhea with granulations, and resistance to local therapy for at
least 8e10 days are highly suggestive of MOE. The presence of
lower cranial nerve palsy (VII, IX, X, XI, and XII) points to the spread
of disease to the skull base and is also an indicator of the extent and
prognosis of the disease.
As shown in Table 1, the most common presenting symptom in
our patients was persistent nocturnal otalgia and ear discharge in
all patients. Two-thirds of patients presented with facial weakness.
All of these patients had granulation in the external auditory canal
(Fig. 1). Three patients had multiple cranial nerve palsy, with
involvement of IX, X, and XII along with VII nerve palsy (Fig. 2).
Sterile swabs from the affected ear are necessary to identify the
organism. It is a practice in our institution to send a sterile swab for
Gram staining, bacterial culture, and fungal smear and culture,
which is processed within 30 minutes to enhance the yield. These
investigations are vital, as early therapy with appropriate antibi-
otics is essential in achieving good cure rates and reduce the
morbidity and mortality known to be associated with this disease.
The most common causative organism implicated in MOE is
Pseudomonas aeruginosa.3,15 Staphylococcus aureus, particularly
methicillin-resistant S. aureus, Staphylococcus epidermidis, Proteus,
and Klebsiella are the other bacteria implicated.16e19 Aspergillus
niger, Aspergillus fumigatus, and Candida species are the common
fungi reported.20,21 It is not knownwhether fungi are the causative
agent or if they only alter the outcome in the management of
MOE. In our study, the most common organisms were P. aeruginosa
(50%, 9/18), S. aureus (22%, 4/18), and Enterococcus faecalis (5.5%,
1/18). Fungal potassium hydroxide (KOH) smearwas positive in 27%
Fig. 4. Computed tomography scan of the skull base showing a homogeneous soft
tissue shadow 2.4 cm  1.5 cm with bone erosion extending from the right petrous
temporal bone and carotid canal (arrows).
Fig. 2. A patient with multiple cranial nerve deﬁcits. VII and XII nerve palsy is shown.
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and Candida was isolated in one patient.
There was no growth in 33% of cases (6/18). This may be due to
the fact that these patients who had already been treated at other
hospitals prior to being referred to us were given oral/intravenous/
topical antibiotics and this might have led to us not being able to
isolate the organism in culture. All of these patients were empiri-
cally treated with antipseudomonal antibiotics by us and they
responded well to treatment. It is emphasized at this stage that
microbiological samples should be taken to identify the organisms
prior to starting on antimicrobial therapy. Twenty-seven per cent
(5/18) of patients with MOE had polymicrobial infection. All
patients in whom fungi were isolated also had positive bacterial
isolates on culture.
High-resolution computed tomography (CT) scan and/or mag-
netic resonance imaging of the temporal bone are a useful adjunct
to clinical diagnosis (Figs. 3 and 4). A high-resolution CT scan of the
temporal bone is the initial imaging modality of choice. It isFig. 3. Computed tomography scan of the skull base, axial section, showing erosion of
the skull base and adjoining clivus (arrows).economical, fast, and also helps in localizing the anatomical limit
and bony involvement. This modality of imaging is not useful in
monitoring resolution of osteomyelitis because bone reminerali-
zation takes time and does not reﬂect the progress of disease.22
Magnetic resonance imaging is useful in monitoring the extent of
soft tissue swelling and also the intracranial extent of disease.22
Radioisotope scans (technetium 99/gallium 67) are useful in
assessing MOE. Gallium 67 is a very sensitive, but nonspeciﬁc test,
detecting and binding to actively-dividing cells. Serial scans can be
done to monitor treatment response and thus help in assessing the
duration of antibiotic therapy.
Treatment involves a multidisciplinary approach, with treat-
ment planned and discussed with the specialist concerned.
Aggressive and adequate control of diabetes, the correction ofFig. 5. Post-treatment improvement in facial nerve function of the same patient
shown in Fig. 2.
Fig. 6. Improvement in hypoglossal nerve functions in the same patient shown in
Fig. 2.
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munity have to be instituted at the earliest opportunity.
We generally start the patient on antipseudomonal penicillins,
piperacillin-tazobactam or ﬂuoroquinolones (ciproﬂoxacin), as the
initial drug of choice. Subsequently, appropriate antibiotics are
administered based on the culture and sensitivity. The antimicro-
bial drug is usually given for a prolonged term (3e6 weeks) and is
based on the relief of signs and symptoms. The patient is dis-
charged with long-term oral ciproﬂoxacin or itraconazole when a
fungus is isolated.
It is debatable whether the fungi are the cause of MOE or inci-
dental ﬁndings. Fungi deﬁnitely inﬂuence the course of disease in
an immunosuppressed host and hence we treated these patients
with oral antifungal itraconazole 100 mg twice daily for 6 weeks
with 2-weekly monitoring of renal and liver function. There were
no adverse reactions to the drug and all patients responded well to
therapy.
We monitored the progress of the disease and treatment
outcome based on clinical evaluation: (1) alleviation of pain and
discharge; (2) disappearance of granulation tissue from the
external auditory canal; (3) improvement in cranial nerve functions
if involved; and (4) return of the total white cell counts and
erythrocyte sedimentation rates to normal values.
The mean duration of treatment in our study was around
3 weeks of intravenous antibiotics followed by oral antibiotics for
6 weeks. Although many authors have reported rapid symptomatic
response with quinolones, it is still recommended to continue
treatment for 6e8 weeks. The era of quinolones has seen a drop in
cases of surgical debridement. Its role has now been reserved for
intractable cases and as a diagnostic tool to differentiate from
malignancy if suspected. We have used surgical debridement in
only three cases in which there was a need to remove sequestrated
bone or drain an abscess.
Two patients had relapse of otalgia after 4e5 months of treat-
ment, but did not show clinical features of active disease in the ear.
At presentation of relapse, they had uncontrolled diabetes. High-
resolution CT scan in both of these patients showed evidence of
skull base osteomyelitis and the patients had to be restarted on
intravenous ciproﬂoxacin followed by oral ciproﬂoxacin along with
control of sugar levels. Poor compliance in taking antidiabetic
medicines is likely to be the cause of relapse.Hyperbaric oxygen is gradually gaining recognition as a bene-
ﬁcial adjuvant therapy. Phillips and Jones in their Cochrane review,
however, concluded that there is no clear evidence that hyperbaric
oxygen is more beneﬁcial than antibiotic therapy.23
Most of our patients (15/18) have recovered from the disease,
with improvement of cranial nerve function (Figs. 5 and 6). We had
two deaths within the 6-month follow up period, but both were
unrelated toMOE; one patient succumbed to complications of renal
failure and another had cardiac arrest.
In conclusion, in this article we have audited our case series and
compared our experience with that of other authors. We recom-
mend that MOE should be suspected in high-risk groups, such as
elderly individuals with diabetes, patients on chemotherapy, or in
those in immunocompromised states. Early and prolonged use of
appropriate antimicrobials will reduce the morbidity and mortality
associated with this condition. The role of surgery for MOE is
limited and only used for diagnosis in the form of biopsy or in some
cases for draining microabscesses or for the removal of seques-
trated bone.References
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